GlobeNewswire by notified

ERYTECH Announces Enrollment of First Patient in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC

Share

LYON, France and CAMBRIDGE, Mass., June 26, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first patient has been enrolled in its Phase 2 clinical trial, named TRYbeCA2,  evaluating its lead product candidate eryaspase for the treatment of first line triple negative breast cancer (TNBC).

Following the positive Phase 2 results with eryaspase in second-line metastatic pancreatic cancer, ERYTECH selected  triple-negative breast cancer as the next indication to expand the potential use of eryaspase in solid tumors. TNBC is an aggressive and metabolically active form of breast cancer with high rates of symptomatic metastases. A Phase 2/3 clinical trial in first-line metastatic TNBC, named TRYbeCA2, was designed and the Phase 2 part of the trial was launched in Spain, Belgium, Hungary and the United Kingdom. The trial is evaluating eryaspase in combination with gemcitabine and carboplatin chemotherapy, compared to chemotherapy alone. Target enrollment in the Phase 2 part of the trial is approximately 64 patients. The primary endpoint is objective response rate.  

“Most women with triple negative breast cancer have very limited treatment options.” stated Iman El Hariry, MD, PhD, Chief Medical Officer of ERYTECH. “Based on accumulated preclinical research of targeting metabolic pathways in TNBC, we believe that the combination of eryaspase with chemotherapy may offer a potential treatment option to these patients. The trial reinforces our strategy to develop medicines that may benefit patients with challenging diseases.”

“I am very pleased that eryaspase, an innovative and promising approach, is evaluated in this Phase 2/3 study in TNBC patients and hopeful that it may provide a novel treatment modality for this highly unmet medical need," commented Prof. Awada, Head of the Medical Oncology Clinic at Jules Bordet Cancer Institute Brussels, Belgium.

About Triple-Negative Breast Cancer (TNBC)

Breast cancer is the most commonly diagnosed cancer in women globally with nearly 2.0 million new cases diagnosed annually1. It is estimated that approximately 800,000 women each year are diagnosed with breast cancer in the United States and Europe in aggregate1, 2. Approximately 10-20% of breast cancers are TNBC, a form of breast cancer that lacks expression of estrogen receptor (ER), progesterone receptor (PR) and does not overexpress HER23.  TNBC is associated with a poorer prognosis when compared to other breast cancer subtypes.  As commonly utilized hormone therapy and HER2 targeting agents are not treatment options for women with TNBC, there is significant unmet need for novel therapeutic approaches in this subtype of breast cancer.

1 World Health Organization (International Agency for Research on Cancer), Globocan 2018
2 Cancer Facts and Figures, 2018 (American Cancer Society)
3 Yam C et al., The Oncologist, September 2017

About ERYTECH: www.erytech.com

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs.

ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is also developing erymethionase, which consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. 

ERYTECH produces product candidates at its GMP-approved manufacturing site in Lyon, France, and at the American Red Cross in Philadelphia, USA. A large-scale GMP manufacturing facility has recently opened for operations in Princeton, New Jersey, USA and will begin manufacturing later this year.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

CONTACTS   
   
ERYTECH    
Eric Soyer
CFO & COO
NewCap
Mathilde Bohin / Louis-Victor Delouvrier
Investor relations
Nicolas Merigeau
Media relations
   
+33 4 78 74 44 38
investors@erytech.com
+33 1 44 71 98 52
erytech@newcap.eu

Forward-looking information

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical results from and the development plans of eryaspase, business and regulatory strategy, expansion of manufacturing capacity and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the potential of ERYTECH’s product pipeline, its clinical development of eryaspase, and the timing of ERYTECH’s preclinical studies and clinical trials and announcements of data from those studies and trials. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s Securities and Exchange Commission (SEC) filings and reports, including in the Company’s 2018 Document de Référence filed with the AMF on March 29, 2019 and in the Company’s Annual Report on Form 20-F filed with the SEC on March 29, 2019 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

AB Traction: Traction publicerar årsredovisningen och årsberättelsen för 202328.3.2024 13:30:00 CET | Pressemelding

AB Traction: Traction publicerar årsredovisningen och årsberättelsen för 2023 Tractions årsredovisning och årsberättelse för 2023 är nu offentliggjorda och finns tillgängliga på bolagets webbplats, www.traction.se Den tryckta versionen av årsberättelsen kan beställas genom e-post till post@traction.se. AB Traction Petter Stillström Verkställande direktör Tel: 08-506 289 00 DENNA INFORMATION ÄR SÅDAN INFORMATION SOM AB TRACTION ÄR SKYLDIGT ATT OFFENTLIGGÖRA ENLIGT LAGEN OM VÄRDEPAPPERSMARKNADEN. INFORMATIONEN LÄMNADES FÖR OFFENTLIGGÖRANDE DEN 28 MARS 2024, KL. 13.30 CET. Bilagor Traction Årsredovisning 2023traction-2023-12-31-svTraction Årsberättelse 2023

Webtel.mobi publishes a detailed article on why the US Dollar is not under threat as Global Reserve Currency, nor a consideration for Global Financial Reform28.3.2024 13:00:46 CET | Press release

NEW YORK and LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Global Telephony Provider Webtel.mobi has published a detailed article describing the real issue and remedy for achievement of Global Financial Reform, required to end the regular “Boom and Bust” cycles. Additionally, a public version of the article follows below Speculation as to the potential ending of the US Dollar’s reign as Global Reserve Currency – or the necessity of that – are both misplaced, according to the Global Telecommunications Company Webtel.mobi. This is, it says, because it is not a Global Currency (any one of them) that creates any global imbalances, weighted advantages or potential reform solutions. It is rather the Global System over which all currencies are transacted that creates all global imbalances, weighted advantages or potential reform solutions. The current Global System is relatively young. It came into being after the end of World War Two, and was provided to the world (or imposed on the world – dep

Digitalist Group Plc has published Financial Statements of 2023, Report by the Board of Directors, Auditor’s Report, Corporate Governance Statement and Remuneration Report28.3.2024 13:00:00 CET | Press release

Digitalist Group Plc Stock Exchange Release 28 March 2024 at 14:00 Digitalist Group Plc has published Financial Statements of 2023, Report by the Board of Directors, Auditor’s Report, Corporate Governance Statement and Remuneration Report Digitalist Group Plc has published the Financial Statements of 2023, the Report by the Board of Directors, the Auditor’s Report, the Corporate Governance Statement and the Remuneration Report in company’s internet pages mentioned below: The financial statements of 2023, which include the Board of Directors' report and the Auditor's report, are published at https://investor.digitalistgroup.com/investor/financial/financial-statements. The Corporate Governance Statement is published at https://investor.digitalistgroup.com/investor/governance. The Remuneration Report is published at https://investor.digitalistgroup.com/investor/governance/remuneration. The Financial Statements of 2023 which include the Board of Directors' report and the Auditor's report,

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors28.3.2024 13:00:00 CET | Press release

David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New Chair LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that Board Chair and co-founder George Goldsmith and fellow co-founder Ekaterina Malievskaia have resigned their seats on the company’s board of directors, effective March 29, 2024. David Norton, lead independent director on the Compass board of directors, will become interim chair. Compass is running a global search for a permanent board chair, focused on recruiting a leader with a strong background in the biotechnology sector and broad strategic experience across the product lifecycle. “When we started Compass eight years ago, we could not have imagined how the company would grow and mature,” said George Goldsmith, outgoing board chair of Compass Pathways. “The comp

Allied Industrial Partners-Backed CES Power Acquires ABird/Apex Power Solutions28.3.2024 12:45:10 CET | Press release

11th Bolt-on Acquisition Expands CES Power’s Global Presence Providing Significant Scale in the U.K. and Europe MEMPHIS, Tenn. and LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- CES Power LLC (“CES Power”), a leading global provider of sustainable mobile power generation, distribution, temperature control and technology solutions for the largest and most complex projects and events, today announced that it has acquired ABird Limited and Apex Generators Limited (“ABird/Apex” or “the Company”), a U.K. supplier of portable power for industrial, corporate and event use. The acquisition was made through CES Power’s global division, CES Global LLC (“CES Global”), which acquired ABird/Apex from U.K. tool and equipment rental and services company HSS Hire Group Plc (LSE: HSS). CES Power is backed by industrial-focused private equity firm Allied Industrial Partners (“Allied”). This strategic acquisition will expand CES Global’s capacity in the U.K. and Ireland while helping to accelerate its growth

HiddenA line styled icon from Orion Icon Library.Eye